文献速递运动医学关节外科

PARP-1抑制对肩袖愈合的影响:在大鼠急性肩袖修复模型中应用维利帕尼的可行性研究

Effect of PARP-1 Inhibition on Rotator Cuff Healing: A Feasibility Study Using Veliparib in a Rat Model of Acute Rotator Cuff Repair.
PubMed 文献 · Am J Sports Med · 2023-02-06

在24只Sprague-Dawley大鼠急性肩袖修复模型中,口服维利帕尼(目标剂量12.5 mg/kg/d)安全且无不良反应,组织学上腱止点分级更优、瘢痕组织更少,冈上肌宏观横截面积高10.5%(P=.034)、显微肌纤维直径高8.7%(P<.0001),但生物力学属性组间无统计学显著差异。

要点

  • 口服维利帕尼在大鼠中安全,未观察到不良反应。
  • 抑制剂组腱止点组织学分级更优且瘢痕组织形成更少。
  • 冈上肌横截面积高10.5%、肌纤维直径高8.7%,但生物力学无显著差异。

核心结论

  • 口服维利帕尼此前已被证明能有效抑制PARP-1,应用安全,对形态学腱止点愈合和肌纤维大小有益。
  • 本研究首次探讨PARP-1抑制对愈合腱止点的影响。

研究设计与样本

  • 控制性实验室研究,24只Sprague-Dawley大鼠,冈上肌腱锐性离断后立即以单根经骨缝线修复。
  • 大鼠随机分为2组,抑制剂组在术后恢复期通过饮水给予维利帕尼,目标剂量12.5 mg/kg/d,术后8周处死。
  • 分析采用宏观、生物力学和组织学方法。

主要发现

  • 口服维利帕尼对大鼠安全,未观察到不良反应。
  • 抑制剂组腱止点组织学分级显著更优,瘢痕组织形成更少。
  • 冈上肌宏观横截面积抑制剂组高10.5%(P=.034)。
  • 组织学切片显微肌纤维直径抑制剂组高8.7%(P<.0001)。
  • 两组生物力学属性无统计学显著差异。

临床怎么用

  • 作者认为,术后愈合期通过PARP-1抑制调节炎症反应是改善腱止点愈合和减少肩袖再撕裂的有前景的方法。
  • 作者认为,使用已获美国食品药品监督管理局批准的药物,PARP-1抑制具有未来转化为临床应用的较高潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PARP-1 (poly[ADP-ribose]) was shown to influence the inflammatory response after rotator cuff tear, leading to fibrosis, muscular atrophy, and fatty infiltration in mouse rotator cuff degeneration. So far, it is not known how PARP-1 influences enthesis healing after rotator cuff tear repair. HYPOTHESIS/PURPOSE: This study aimed to examine the feasibility of oral PARP-1 inhibition and investigate its influence on rat supraspinatus enthesis and muscle healing after rotator cuff repair. The hypothesis was that oral PARP-1 inhibition would improve enthesis healing after acute rotator cuff repair in a rat model. STUDY DESIGN: Controlled laboratory study. METHODS: In 24 Sprague-Dawley rats, the supraspinatus tendon was sharply detached and immediately repaired with a single transosseous suture. The rats were randomly allocated into 2 groups, with the rats in the inhibitor group receiving veliparib with a target dose of 12.5 mg/kg/d via drinking water during the postoperative recovery period. The animals were sacrificed 8 weeks after surgery. For the analysis, macroscopic, biomechanical, and histologic methods were used. RESULTS: Oral veliparib was safe for the rats, with no adverse effects observed. In total, the inhibitor group had a significantly better histologic grading of the enthesis with less scar tissue formation. The macroscopic cross-sectional area of the supraspinatus muscles was 10.5% higher (P = .034) in the inhibitor group, which was in agreement with an 8.7% higher microscopic muscle fiber diameter on histologic sections (P < .0001). There were no statistically significant differences in the biomechanical properties between the groups. CONCLUSION: This study is the first to investigate the influence of PARP-1 inhibition on healing enthesis. On the basis of these findings, we conclude that oral veliparib, which was previously shown to inhibit PARP-1 effectively, is safe to apply and has beneficial effects on morphologic enthesis healing and muscle fiber size. CLINICAL RELEVANCE: Modulating the inflammatory response through PARP-1 inhibition during the postoperative healing period is a promising approach to improve enthesis healing and reduce rotator cuff retearing. With substances already approved by the Food and Drug Administration, PARP-1 inhibition bears high potential for future translation into clinical application.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Künzler MB, McGarry MH, Akeda M, et al. Effect of PARP-1 Inhibition on Rotator Cuff Healing: A Feasibility Study Using Veliparib in a Rat Model of Acute Rotator Cuff Repair. Am J Sports Med. 2023. PMID: 36745049. doi:10.1177/03635465221148494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。